← All trials
NCT04609878
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- Jul 25, 2023
- Completion date
- Jul 25, 2023
- First posted
- Oct 30, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 2800
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Royal Brompton Hospital, United KingdomOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.